Protocol Ledger

NCT04255589 · Phase III · COMPLETED

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

Interventional Phase III clinical trial protocol NCT04255589 sponsored by Chong Kun Dang Pharmaceutical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-06 Enrollment: 242 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04255589
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)242 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04255589
Protocol FieldVerified Registry Value
NCT IdentifierNCT04255589
Consolidated Lead SponsorChong Kun Dang Pharmaceutical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment242 participants (ACTUAL)
Registered Start Date2020-01-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04255589
Hospital Research SiteLocationSite Profile
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
Seoul National University Bundang HospitalSeongnam, South KoreaOpen Hospital Dossier ->
Chung-Ang University HospitalSeoul, South KoreaOpen Hospital Dossier ->
Kangbuk Samsung HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI